Extended trial tests if new nerve disease drug remains safe for years
NCT ID NCT05071300
Summary
This study follows patients who previously participated in earlier trials of eplontersen, a medication for hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), a rare nerve disease. Researchers want to see if the drug remains safe and effective when taken for up to two additional years. The study tracks side effects, nerve function, and quality of life in about 151 patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOID POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston University School of Medicine
Boston, Massachusetts, 02118, United States
-
Centre Hospitalier Universitaire de Toulouse
Toulouse, Haute-Garonne, 31059, France
-
Centro Hospitalar Universitário Lisboa Norte - Hospital De Santa Maria
Lisbon, 1649-035, Portugal
-
Centro Hospitalar Universitário do Porto - Hospital Geral de Santo Antonio
Porto, 4099-001, Portugal
-
Chang Gung Memorial Hospital
Taoyuan District, 333, Taiwan
-
China Medical University Hospital
Taichung, 40447, Taiwan
-
Fondazione IRCCS Policlinico San Matteo
Pavia, 27100, Italy
-
Hospital Clínico San Carlos
Madrid, 28040, Spain
-
Hospital El Cruce
San Juan Bautista, 1888, Argentina
-
Hospital Italiano de Buenos Aires
Buenos Aires, C1199ABB, Argentina
-
Hospital Son Llàtzer
Palma de Mallorca, 07198, Spain
-
Hospital Universitario Clementino Fraga Filho
Botafogo, Rio de Janeiro, 22281-100, Brazil
-
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto
São Paulo, 14051-140, Brazil
-
Hôpital de la Timone
Marseille, 13385, France
-
Indiana University Health University Hospital
Indianapolis, Indiana, 46202, United States
-
Instituto Fleni
Buenos Aires, C1428 AQK, Argentina
-
Instituto de Neurologia de Curitiba
Curitiba, 81210-310, Brazil
-
Istanbul Üniversitesi - Istanbul Tip Fakültesi
Istanbul, 34093, Turkey (Türkiye)
-
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Fondazione Istituto Neurologico Carlo Besta
Milan, 20133, Italy
-
Johns Hopkins University Neurology Research Office
Baltimore, Maryland, 21287, United States
-
Mayo Clinic
Scottsdale, Arizona, 85259, United States
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
Norrlands Universitetssjukhus
Umeå, 901 85, Sweden
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Perron Institute for Neurological and Translational Science
Murdoch, Western Australia, 6150, Australia
-
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
-
The Cyprus Institute of Neurology and Genetics
Égkomi, 2371, Cyprus
-
The Neurological Institute of New York
New York, New York, 10032, United States
-
Toronto General Hospital
Toronto, Ontario, M5G2C4, Canada
-
Universidade Estadual de Campinas
Campinas, 13083-888, Brazil
-
University of North Carolina Hospitals - Neurology Clinic
Chapel Hill, North Carolina, 27514, United States
-
University of Washington Medical Center
Seattle, Washington, 98195, United States
-
Vancouver General Hospital
Vancouver, British Columbia, V5Z 1M9, Canada
Conditions
Explore the condition pages connected to this study.